Impact of Prior Use of an Androgen Receptor-Axis-Targeted (ARAT) Agent With or Without Subsequent Taxane Therapy on the Efficacy of Another ARAT Agent in Patients With Metastatic Castration-Resistant Prostate Cancer
Authors:
- 1 April 2017
- journal article
- research article
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 15 (2) , e217-e222
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- What do we know about treatment sequencing of abiraterone, enzalutamide, and chemotherapy in metastatic castration-resistant prostate cancer?World Journal of Urology, 2015
- Treatment of mCRPC in the AR-axis-targeted therapy-resistant stateAnnals of Oncology, 2015
- Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 studyThe Lancet Oncology, 2015
- Enzalutamide in Metastatic Prostate Cancer before ChemotherapyNew England Journal of Medicine, 2014
- No clear evidence of a clinical benefit of a sequential therapy regimen with abiraterone acetate and enzalutamideExpert Review of Anticancer Therapy, 2014
- Optimal management of metastatic castration-resistant prostate cancer: Highlights from a European Expert Consensus PanelEuropean Journal of Cancer, 2014
- Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 studyThe Lancet Oncology, 2012
- Increased Survival with Enzalutamide in Prostate Cancer after ChemotherapyNew England Journal of Medicine, 2012
- Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate CancerNew England Journal of Medicine, 2004
- Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate CancerNew England Journal of Medicine, 2004